SCHEMBL4863931

SCHEMBL4863931

CCn1c(=O)c([N+](=O)[O-])c(-c2cnn(-c3ccccc3)c2)n(CCCOC)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.44
ADORA2B P29275 11/20 0.44
ADORA1 P30542 4/20 0.42
HSP90AA1 P07900 1/20 0.39
GRM4 Q14833 2/20 0.39
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
MITF O75030 1/20 0.36
AGTR1 P30556 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TLR9 Q9NR96 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865556 0.90 ADORA2A (0.45) ADORA2AADORA2BADORA1HSP90AA1GRM4
SCHEMBL4866210 0.90 ADORA2B (0.45) ADORA2AADORA2BADORA1HSP90AA1GRM4
SCHEMBL4863501 0.88 HSP90AA1 (0.46) ADORA2AADORA2BADORA1HSP90AA1GRM4
SCHEMBL4863923 0.88 ADORA2A (0.51) ADORA2AADORA2BADORA1HSP90AA1GRM4
SCHEMBL4868526 0.87 ADORA2B (0.50) ADORA2AADORA2BADORA1HSP90AA1GRM4
SCHEMBL4865970 0.86 ADORA2B (0.40) ADORA2AADORA2BALDH1A1LMNAMAPT
SCHEMBL4866073 0.85 ADORA2B (0.55) ADORA2AADORA2BADORA1HSP90AA1ALDH1A1
SCHEMBL4866844 0.83 ADORA1 (0.44) ADORA2AADORA2BADORA1HSP90AA1ALDH1A1
SCHEMBL4765291 0.82 NPC1 (0.40) ADORA2AADORA2BADORA1ALDH1A1LMNA
SCHEMBL4859057 0.81 ADORA2B (0.46) ADORA2AADORA2BADORA1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ADORA2A 2/4885ADORA2B 1/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.